These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22687143)

  • 1. Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study.
    Leoutsakos JM; Han D; Mielke MM; Forrester SN; Tschanz JT; Corcoran CD; Green RC; Norton MC; Welsh-Bohmer KA; Lyketsos CG
    Int Psychogeriatr; 2012 Oct; 24(10):1561-70. PubMed ID: 22687143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study.
    Tschanz JT; Corcoran CD; Schwartz S; Treiber K; Green RC; Norton MC; Mielke MM; Piercy K; Steinberg M; Rabins PV; Leoutsakos JM; Welsh-Bohmer KA; Breitner JC; Lyketsos CG
    Am J Geriatr Psychiatry; 2011 Jun; 19(6):532-42. PubMed ID: 21606896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychiatric Symptoms as Risk Factors for Cognitive Decline in Clinically Normal Older Adults: The Cache County Study.
    Burhanullah MH; Tschanz JT; Peters ME; Leoutsakos JM; Matyi J; Lyketsos CG; Nowrangi MA; Rosenberg PB
    Am J Geriatr Psychiatry; 2020 Jan; 28(1):64-71. PubMed ID: 31186157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD).
    Oh ES; Rosenberg PB; Rattinger GB; Stuart EA; Lyketsos CG; Leoutsakos JS
    J Am Geriatr Soc; 2021 Apr; 69(4):955-963. PubMed ID: 33382921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
    Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
    Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.
    Rosenberg PB; Mielke MM; Han D; Leoutsakos JS; Lyketsos CG; Rabins PV; Zandi PP; Breitner JC; Norton MC; Welsh-Bohmer KA; Zuckerman IH; Rattinger GB; Green RC; Corcoran C; Tschanz JT
    Int J Geriatr Psychiatry; 2012 Dec; 27(12):1248-57. PubMed ID: 22374884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes.
    Haaksma ML; Calderón-Larrañaga A; Olde Rikkert MGM; Melis RJF; Leoutsakos JS
    Int J Geriatr Psychiatry; 2018 Aug; 33(8):1057-1064. PubMed ID: 29761569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease.
    Rosenberg PB; Mielke MM; Tschanz J; Cook L; Corcoran C; Hayden KM; Norton M; Rabins PV; Green RC; Welsh-Bohmer KA; Breitner JC; Munger R; Lyketsos CG
    Am J Geriatr Psychiatry; 2008 Nov; 16(11):883-92. PubMed ID: 18978249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease.
    Mielke MM; Leoutsakos JM; Tschanz JT; Green RC; Tripodis Y; Corcoran CD; Norton MC; Lyketsos CG
    J Alzheimers Dis; 2011; 26(1):127-34. PubMed ID: 21593560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study.
    Hallikainen I; Hänninen T; Fraunberg M; Hongisto K; Välimäki T; Hiltunen A; Karppi P; Sivenius J; Soininen H; Koivisto AM;
    Int Psychogeriatr; 2013 Aug; 25(8):1335-44. PubMed ID: 23676340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular factors predict rate of progression in Alzheimer disease.
    Mielke MM; Rosenberg PB; Tschanz J; Cook L; Corcoran C; Hayden KM; Norton M; Rabins PV; Green RC; Welsh-Bohmer KA; Breitner JC; Munger R; Lyketsos CG
    Neurology; 2007 Nov; 69(19):1850-8. PubMed ID: 17984453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of Alzheimer's Disease: A Longitudinal Study in Norwegian Memory Clinics.
    Eldholm RS; Barca ML; Persson K; Knapskog AB; Kersten H; Engedal K; Selbæk G; Brækhus A; Skovlund E; Saltvedt I
    J Alzheimers Dis; 2018; 61(3):1221-1232. PubMed ID: 29254085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.
    Mielke MM; Leoutsakos JM; Corcoran CD; Green RC; Norton MC; Welsh-Bohmer KA; Tschanz JT; Lyketsos CG
    Alzheimers Dement; 2012 May; 8(3):180-7. PubMed ID: 22301194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nutritional Status is Associated with Faster Cognitive Decline and Worse Functional Impairment in the Progression of Dementia: The Cache County Dementia Progression Study1.
    Sanders C; Behrens S; Schwartz S; Wengreen H; Corcoran CD; Lyketsos CG; Tschanz JT
    J Alzheimers Dis; 2016 Feb; 52(1):33-42. PubMed ID: 26967207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychiatric symptoms as risk factors for progression from CIND to dementia: the Cache County Study.
    Peters ME; Rosenberg PB; Steinberg M; Norton MC; Welsh-Bohmer KA; Hayden KM; Breitner J; Tschanz JT; Lyketsos CG;
    Am J Geriatr Psychiatry; 2013 Nov; 21(11):1116-24. PubMed ID: 23567370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study.
    Peterson D; Munger C; Crowley J; Corcoran C; Cruchaga C; Goate AM; Norton MC; Green RC; Munger RG; Breitner JC; Welsh-Bohmer KA; Lyketsos C; Tschanz J; Kauwe JS;
    Alzheimers Dement; 2014 May; 10(3):366-71. PubMed ID: 23727081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cohort Effects in Progression Rate on Cognitive and Functional Measures in an Alzheimer's Disease Clinical Cohort.
    Pavlik VN; Chan W; Darby E
    J Alzheimers Dis; 2019; 71(2):659-669. PubMed ID: 31424408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.
    Steinberg M; Hess K; Corcoran C; Mielke MM; Norton M; Breitner J; Green R; Leoutsakos J; Welsh-Bohmer K; Lyketsos C; Tschanz J
    Int J Geriatr Psychiatry; 2014 Feb; 29(2):153-9. PubMed ID: 23681754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study.
    Peters ME; Schwartz S; Han D; Rabins PV; Steinberg M; Tschanz JT; Lyketsos CG
    Am J Psychiatry; 2015 May; 172(5):460-5. PubMed ID: 25585033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study.
    Leoutsakos JM; Forrester SN; Corcoran CD; Norton MC; Rabins PV; Steinberg MI; Tschanz JT; Lyketsos CG
    Int J Geriatr Psychiatry; 2015 Aug; 30(8):824-32. PubMed ID: 25363393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.